Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
KURA Stock Chart & Stats
$9.77
-$0.35(-4.35%)
At close: 4:00 PM EST
$9.77
-$0.35(-4.35%)
Day’s Range― - ―
52-Week Range$5.41 - $19.73
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.88M
Market Cap
$891.41M
Enterprise Value-$105.88M
Total Cash (Recent Filing)$630.73M
Total Debt (Recent Filing)$12.96M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Mar 03, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding86,797,190
10 Day Avg. Volume2,163,441
30 Day Avg. Volume1,876,670
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-1.27
Enterprise Value/Gross Profit-1.28
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$26.00Price Target Upside166.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Drug Approval PotentialThe expansion of Revuforj’s label is seen as a positive indication for the potential approval of ziftomenib in NPM1-m patients.
Market PositioningThere is confidence in Kura's ability to bring its first commercial asset to market due to ziftomenib’s competitive benefit-risk profile.
Safety ProfileZiftomenib demonstrates comparable efficacy but improved tolerability compared to Revuforj, suggesting a meaningful safety advantage.
Bears Say
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.41 and its highest was $19.73 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $891.41M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Mar 03, 2026 which is in 119 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Nov 04, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.12.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.28.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 86,797,190 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went down -7.047%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
Kura Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (166.12% Upside)
$26.00 (166.12% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $198.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.57%
12-Months-Change
Fundamentals
Return on Equity
-51.11%
Trailing 12-Months
Asset Growth
32.48%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. (KURA) is a biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of cancer. The company is involved in the research and development of small molecule drug candidates primarily targeting genetically defined patient populations. Its core products include tipifarnib, ziftomenib, and KO-2806, which are in various stages of clinical trials for different types of cancer, such as acute myeloid leukemia and other solid tumors.
KURA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong clinical trial results, regulatory progress, and financial stability, indicating positive momentum for Kura Oncology's lead program, ziftomenib, and its pipeline. However, increased expenses and net loss present financial challenges. The sentiment is positive overall due to significant advancements and strong financial positioning.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$26.00
▲(166.12% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Ownership Overview
1.83% Insiders
10.82% Mutual Funds
1.64% Other Institutional Investors
72.06% Public Companies and
Individual Investors